Recordati (Italy)

Recent papers from Recordati (Italy)

1. Morbidity burden and healthcare costs in idiopathic multicentric Castleman disease (BURDEN-iMCD): a retrospective population-level matched cohort analysisJournal of Medical Economics · 2026
2. Cost−effectiveness of pasireotide as second−line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health SystemFrontiers in Endocrinology · 2026
3. Combined Tribenoside/Lidocaine Rectal Cream (Procto-Glyvenol®) Promotes Tissue Repair in a Preclinical Model of Acute Complicated Anal FissurePharmaceuticals · 2026
4. Age‐specific melanoma risk associated with nevi: a pooled analysis from the M‐SKIP projectJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2026
5. Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist’s perspectiveAmerican Journal of Clinical Pathology · 2025
6. Public Perspectives on Artificial Intelligence in Medicine and Radiology: Insights From a Survey in an Italian Cancer Referral CenterJCO Clinical Cancer Informatics · 2026
7. Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessmentJournal of Medical Economics · 2026
8. Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapyiScience · 2025
9. Discrepancies in regulations in post-marketing safety surveillance of drug-device combination products in the EU and US: a reviewFrontiers in Drug Safety and Regulation · 2025
10. Real-world osilodrostat effectiveness and safety in non-pituitary Cushing syndromeThe Journal of Clinical Endocrinology & Metabolism · 2025
11. Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing SyndromeThe Journal of Clinical Endocrinology & Metabolism · 2025
12. Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerEuropean Journal of Cancer · 2025
13. Osilodrostat dose impact on efficacy/safety in Cushing’s disease: Large, pooled analysis of LINC 2, 3 and 4European Journal of Endocrinology · 2025
14. Structure-based design of potent and selective inhibitors of the HECT ligase NEDD4Communications Chemistry · 2025
15. Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studiesPituitary · 2025
16. Recommended methods for the collection of clinical expert judgment in rare diseases: Generating evidence to support reimbursement of orphan drugsInternational Journal of Technology Assessment in Health Care · 2025
17. A multiparametric screen uncovers FDA-approved small molecules that potentiate the nuclear mechano-dysfunctions in ATR-defective cellsScientific Reports · 2024
18. Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free CortisolJournal of the Endocrine Society · 2024
19. 6907 Continued Improvements in Hypertension and Diabetes During Long-Term Osilodrostat Therapy in Patients with Cushing’s Disease: A Pooled Analysis from the Phase III LINC 3 and LINC 4 StudiesJournal of the Endocrine Society · 2024
20. 12275 Effect Of Osilodrostat On Cardiovascular And Metabolic Manifestations Of Hypercortisolism In Patients With Non-Pituitary Cushing’s Syndrome: Findings From A Retrospective Observational Study (LINC 7)Journal of the Endocrine Society · 2024